Pulmonary-Allergy Drugs Advisory Committee; Amendment of Notice

ローカル自動翻訳 · 情報源の原言語

概要

The Food and Drug Administration (FDA) is announcing an amendment to the notice of meeting of the Pulmonary-Allergy Drugs Advisory Committee. This meeting was announced in the Federal Register of September 8, 2022. The amendment is being made to reflect changes in the DATES, ADDRESSES, and SUPPLEMENTARY INFORMATION portions of the document. The meeting was rescheduled to allow time for FDA to review new information submitted to the application. There are no other changes.

情報源の原言語: Federal Register — Food and Drug Administration原文の発表を開く →

Pulmonary-Allergy Drugs Advisory Committee; Amendment of Notice

Office of Management and Budget (OMB) に提出された情報収集活動; Food and Drug Administration (FDA) の提出書類の提出; Customer/Partner Customer Service Satisfaction Surveys に関するコメントの要求

Office of the National Coordinator for Health Information Technology; Health Information Technology Advisory Committee; エンタイントにそすにしたプログルにしたプログにプログを定义にしたプログに。